PDF factsheet
      Z

All mechanism in heart failure with preserved LVEF for all type of patients, clinical trials results

candesartan versus placebo
CHARM preserved, 2003
candesartan target dose 32 mg once daily
versus
placebo
patients with NYHA II-IV heart failure and LVEF higher than 40%double blind
Follow-up duration: 36.6 months
26 countries
ibesartan versus placebo
I-PRESERVE (McMurray), 2008
NCT00095238
ibersatan 300mg daily
versus
placebo
patients with NYHA II, III, or IV heart failure and an ejection fraction of at least 45%double blind
Follow-up duration: 49.5 months
Western Europe, Eastern Europe, North America, South America, South Africa, and Australia
LCZ696 versus valsartan
PARAMOUNT, 2012
NCT00887588
LCZ696 titrated to 200 mg twice daily for 36 weeks
versus
valsartan titrated to 160 mg twice daily,
double-blind
Follow-up duration: 12 weeks
perindopril versus placebo
PEP CHF, 2006
perindopril, 4 mg/day
versus
placebo
patients aged >=70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve diseasedouble blind
Follow-up duration: 26.2 months (range 12-54.2m)
Europe
spironolactone versus placebo
TOPCAT, 2014
NCT00094302
spironolactone (15 to 45 mg daily)
versus
placebo
patients with heart failure and a preserved left ventricular ejection fraction of 45% or more double-blind
Follow-up duration: 3.3 years

  Options


in first

in second

  Filter